Keros Therapeutics is experiencing a decline in its stock price today following the company's decision to halt higher doses in a lung disease study due to side effects. This development, which was reported on December 17, 2024, has raised concerns among investors about the potential impact on the company's pipeline and future prospects. The decision to stop administering higher doses in the study of cibotercept for pulmonary hypertension has likely contributed to the negative sentiment surrounding the stock.
Keros Therapeutics (KROS) shares are currently trading at $18.10, down 6.80% from the previous close of $19.42 and 6.36% lower than the opening price of $19.33.